Disease-modifying therapies market is expected to reach US$ 112.64 Billion by 2033 | Genentech USA Inc., Novartis AG, Teva Neuroscience Inc, GSK, AstraZeneca, AbbVie Inc, Amgen Inc

Global disease-modifying therapies market size was US$ 65.32 Billion in 2024 and is expected to reach US$ 112.64 Billion by 2033, growing at a CAGR of 6.2% during the forecast period 2025-2033

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/disease-modifying-therapies-market?sg

Major Deals & M&A:

✅ 2025‐04‐30: Novartis agreed to acquire Regulus Therapeutics for up to USD 1.7 billion, primarily to gain its lead investigational DMT candidate farabursen (for autosomal dominant polycystic kidney disease, ADPKD). The deal includes USD 0.8 bn upfront, plus contingent value rights for regulatory milestones.

✅ 2025‐06‐25: Novartis completed the acquisition Regulus is now an indirect subsidiary of Novartis, positioning farabursen for accelerated development under a large pharma able to support global trials.

New Approvals / Launches & Regulatory Milestones (2025)

✅ 2025‐11‐24: The Itvisma (onasemnogene abeparvovec‐brve) gene therapy from Novartis - was approved by the US FDA for treatment of Spinal Muscular Atrophy (SMA) in patients aged 2 years and older with a specific SMN1 mutation. This expands the gene‐therapy option beyond infants (the prior age limit for Zolgensma).

Clinical Development & Pipeline Progress (New/Promising DMTs)

✅ 2025‐04‐02: Ocrevus (ocrelizumab) already a standard DMT for multiple sclerosis (MS) had its high‐dose Phase III "MUSETTE" trial results announced: the high-dose IV version did not show added benefit over the standard 600 mg IV dose in slowing disability progression in relapsing MS; safety profile remained acceptable. This reinforces the 600 mg dose as the optimal regimen.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/disease-modifying-therapies-market?sg

Key growth drivers:

✅ Unmet need & ageing populations - rising prevalence of neurodegenerative diseases (Alzheimer's) and autoimmune disorders increases demand for true disease-modifying options.

✅ Wave of advanced modalities (gene, cell, RNA therapeutics) - approvals and label expansions (recent gene-therapy approvals and launches) are commercializing once-experimental approaches and creating new, high-value markets.

✅ Large R&D investment and clinical pipeline - many late-stage small molecules and biologics aiming for disease modification (especially in Alzheimer's and rare genetic diseases) are pushing forecasted growth.

✅ Improving diagnostics & patient identification - better biomarkers and screening (e.g., earlier Alzheimer's diagnosis) increase eligible patient pools for DMTs.

✅ Favorable commercial dynamics for breakthrough therapies - high prices for one-time or durable therapies (gene therapies) attract investment despite reimbursement debate, creating large near-term revenues for approved DMTs.

Regional share & dynamics:

➠ North America - market leader. Highest share driven by R&D concentration, early regulatory approvals, and payer willingness to reimburse high-cost advanced therapies. (US accounts for the bulk of DMT commercial sales today).

➠ Europe - #2 with strong institutional adoption. Solid reimbursement infrastructure and large patient populations for neuro/autoimmune indications keep Europe an important market.

➠ Asia-Pacific - fastest growth (highest CAGR). Rising healthcare spending, capacity building, and improving access mean APAC is the fastest-growing regional market for DMT adoption (longer term catch-up potential).

Segments Covered in the Disease-Modifying Therapies (DMT) Market:

By Drug Class (Biologics, Small Molecule Drugs)

By Disease Indication (Multiple Sclerosis, Rheumatoid Arthritis, Lupus, Crohn's Disease, and Other)

By Route of Administration (Parenteral, Oral)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)

Regional Analysis for Disease-Modifying Therapies (DMT) Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=disease-modifying-therapies-market?sg

Major Key Players: Genentech USA, Inc.; Novartis AG; Teva Neuroscience, Inc.; GSK; AstraZeneca; Johnson & Johnson; AbbVie Inc.; Amgen Inc.; UCB, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Disease-Modifying Therapies (DMT) market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Disease-Modifying Therapies (DMT) Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Disease-Modifying Therapies (DMT) market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Disease-Modifying Therapies (DMT) Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.